Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Giant Cell Glioblastoma
- Analgesics
- Analgesics Non-narcotic
- Anti-infective Agents
- Antiviral Agents
- Astrocytoma, Grade IV
- Cyclophosphamide
- Glioblastoma Multiforme
- Sensory System Agents
- Physiological Effects of Drugs
- Immunologic Factors
- Immunosuppressive Agents
- Peripheral Nervous System Agents
- Molecular Mechanisms of Pharmacological Action
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: 2 modalities Systemic vs Intratumoral. For systemic experimental: Cyclophosphamide at Day -3 followed by CYNK-001. On Days 0, 7, and 14. Experimental IntraTumoral, Ommaya placement surgery 7 days prior to CYNK-001 administrations at Days 0, 7 and 14Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04489420
- Collaborators
- Not Provided
- Investigators
- Study Director: Kris Grzegorzewski, MD Celularity inc.
Get Well Soon